MEDICINOVA INCMNOVEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Medicinova Inc. is a clinical-stage biopharmaceutical firm developing novel therapies for unmet medical needs, focusing on immunology, inflammatory disorders and oncology. It operates across North America and Asia, advancing pipeline candidates through clinical trials to serve patients with limited treatment options.
MNOV Q3 FY2025 Key Financial Metrics
Revenue
$123.3K
Gross Profit
N/A
Operating Profit
$-3.4M
Net Profit
$-3.1M
Gross Margin
N/A
Operating Margin
-2741.7%
Net Margin
-2473.6%
YoY Growth
N/A
EPS
$-0.06
MEDICINOVA INC Q3 FY2025 Financial Summary
MEDICINOVA INC reported revenue of $123.3K for Q3 FY2025, with a net profit of $-3.1M (down 6.9% YoY) (-2473.6% margin).
Key Financial Metrics
| Total Revenue | $123.3K |
|---|---|
| Net Profit | $-3.1M |
| Gross Margin | N/A |
| Operating Margin | -2741.7% |
| Report Period | Q3 FY2025 |
MEDICINOVA INC Quarterly Revenue & Net Profit History
MEDICINOVA INC results over the last 2 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $123.3K | — | $-3.1M | -2473.6% |
| Q2 FY2025 | $134.6K | — | $-3.3M | -2437.7% |
Income Statement
| Q2 2025 | Q3 2025 | |
|---|---|---|
| Revenue | $134599 | $123319 |
| YoY Growth | N/A | N/A |
Balance Sheet
| Q2 2025 | Q3 2025 | |
|---|---|---|
| Assets | $49.8M | $47.6M |
| Liabilities | $3.0M | $3.6M |
| Equity | $46.9M | $44.0M |
Cash Flow
| Q2 2025 | Q3 2025 | |
|---|---|---|
| Operating CF | $-2.3M | $-1.7M |